Corrigendum to "Gene therapy for restenosis: Biological solution to a biological problem" [J. Mol. Cell. Cardiol. 42 (2007) 461-468] (DOI:10.1016/j.yjmcc.2006.11.012);Gene therapy for restenosis: Biological solution to a biological problem

Journal of Molecular and Cellular Cardiology

Volumn 42, Issue 3, 2007, Pages 461-468

  Kishore, Raj ^a   Losordo, Douglas W ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Proliferation; Re endothelialization; Restenosis

Indexed keywords

CYCLIN G1; CYTOSINE DEAMINASE; FAS LIGAND; FLUOROURACIL; GANCICLOVIR; INDUCIBLE NITRIC OXIDE SYNTHASE; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN P21; PROTEIN P27; PROTEIN P53; RAPAMYCIN; STRESS ACTIVATED PROTEIN KINASE; THYMIDINE KINASE; TRANSCRIPTION FACTOR E2F1;

ARTERY INTIMA PROLIFERATION; CELL MIGRATION; CORONARY ARTERY DISEASE; CORONARY STENT; CYTOSTASIS; CYTOTOXICITY; DNA MODIFICATION; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESTENOSIS; REVIEW; THROMBOGENESIS; VIRAL GENE DELIVERY SYSTEM;

EID: 33847369045     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2007.04.013     Document Type: Erratum

References (94)

1. Holmes Jr. D.R., Leon M.B., Moses J.W., Popma J.J., Cutlip D., Fitzgerald P.J., et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109 (2004) 634-640
2. Weisz G., Leon M.B., Holmes Jr. D.R., Kereiakes D.J., Clark M.R., Cohen B.M., et al. Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. J. Am. Coll. Cardiol. 47 (2006) 1350-1355
3. Kataoka T., Grube E., Honda Y., Morino Y., Hur S.H., Bonneau H.N., et al. 7-Hexanoyltaxol-eluting stent for prevention of neointimal growth: an intravascular ultrasound analysis from the Study to COmpare REstenosis rate between QueST and QuaDS-QP2 (SCORE). Circulation 106 (2002) 1788-1793
4. Isner J.M., and Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J. Clin. Invest. 103 (1999) 1231-1236
5. Santiago F.S., and Khachigian L.M. Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. J. Mol. Med. 79 (2001) 695-706
6. Andres V., and Castro C. Antiproliferative strategies for the treatment of vascular proliferative disease. Curr. Vasc. Pharmacol. 1 (2003) 85-98
7. Melo L.G., Pachori A.S., Kong D., Gnecchi M., Wang K., Pratt R.E., et al. Gene and cell-based therapies for heart disease. FASEB J. 18 (2004) 648-663
8. Ross R., Masuda J., and Raines E.W. Cellular interactions, growth factors, and smooth muscle proliferation in atherogenesis. Ann. N. Y. Acad. Sci. 598 (1990) 102-112
9. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126 (Review)
10. Muller D.W., Ellis S.G., and Topol E.J. Experimental models of coronary artery restenosis. J. Am. Coll. Cardiol. 19 (1992) 418-442
11. O'Sullivan M., and Bennett M.R. Gene therapy for coronary restenosis: is the enthusiasm justified?. Heart 86 (2001) 491-493 (Review)
12. Appleby C.E., Kingston P.A., David A., Gerdes C.A., Umana P., Castro M.G., et al. A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer. Gene Ther. 10 (2003) 1616-1622
13. Nabel E.G., Plautz G., Boyce F.M., Stanley J.C., and Nabel G.J. Recombinant gene expression in vivo within endothelial cells of the arterial wall. Science 244 (1989) 1342-1344
14. Ohno T., Gordon D., San H., Pompili V.J., Imperiale M.J., Nabel G.J., et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265 (1994) 781-784
15. Guzman R.J., Hirschowitz E.A., Brody S.L., Crystal R.G., Epstein S.E., and Finkel T. In vivo suppression of injury-induced vascular smooth muscle cell accumulation using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 10732-10736
16. Barbee R.W., Stapleton D.D., Madras D.E., Re R.N., Murgo J.P., Davenport W.D., et al. Retroviral suicide vector does not inhibit neointimal growth in a porcine coronary model of restenosis. Biochem. Biophys. Res. Commun. 207 (1995) 89-98
17. Varenne O., and Sinnaeve P. Gene therapy for coronary restenosis: a promising strategy for the new millennium?. Curr. Interv. Cardiol. Rep. 2 (2000) 309-315
18. Hu W.Y., Fukuda N., Kotani M., and Kanmatsuse K. Adenovirus-mediated transfer of ribozyme targeting platelet-derived growth factor A-chain mRNA inhibits growth of vascular smooth muscle cells from spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 39 (2002) 858-865
19. Steg P.G., Benacerraf M., Chatel D., and Laissy J.P. Images in cardiovascular medicine. False aortic aneurysm due to rupture of an aortocoronary saphenous vein bypass graft. Circulation 96 (1997) 3778
20. Simari R.D., San H., Rekhter M., Ohno T., Gordon D., Nabel G.J., et al. Regulation of cellular proliferation and intimal formation following balloon injury in atherosclerotic rabbit arteries. J. Clin. Invest. 98 (1996) 225-235
21. Harrell R.L., Rajanayagam S., Doanes A.M., Guzman R.J., Hirschowitz E.A., Crystal R.G., et al. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation 96 (1997) 621-627
22. Sata M., Perlman H., Muruve D.A., Silver M., Ikebe M., Libermann T.A., et al. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 1213-1217
23. Luo Z., Sata M., Nguyen T., Kaplan J.M., Akita G.Y., and Walsh K. Adenovirus-mediated delivery of fas ligand inhibits intimal hyperplasia after balloon injury in immunologically primed animals. Circulation 99 (1999) 1776-1779
24. Xu F., Prescott M.F., Liu P.X., Chen Z.H., Liau G., Gordon E.M., et al. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. Int. J. Mol. Med. 8 (2001) 19-30
25. Rivard A., and Andres V. Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases. Histol. Histopathol. 15 (2000) 557-571
26. Chang M.W., Barr E., Seltzer J., Jiang Y.Q., Nabel G.J., Nabel E.G., et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267 (1995) 518-522
27. Smith R.C., Wills K.N., Antelman D., Perlman H., Truong L.N., Krasinski K., et al. Adenoviral constructs encoding phosphorylation-competent full-length and truncated forms of the human retinoblastoma protein inhibit myocyte proliferation and neointima formation. Circulation 96 (1997) 1899-1905
28. Claudio P.P., Fratta L., Farina F., Howard C.M., Stassi G., Numata S., et al. Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty. Circ. Res. 85 (1999) 1032-1039
29. Goukassian D.A., Kishore R., Krasinski K., Dolan C., Luedemann C., Yoon Y.S., et al. Engineering the response to vascular injury: divergent effects of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells result in endothelial recovery and inhibition of neointimal growth. Circ. Res. 93 (2003) 162-169
30. Huehns T.Y., Krausz E., Mrochen S., Schmid M., Engelmann M.G., Esin S., et al. Neointimal growth can be influenced by local adventitial gene manipulation via a needle injection catheter. Atherosclerosis 144 (1999) 135-150
31. Chen D., Krasinski K., Sylvester A., Chen J., Nisen P.D., and Andres V. Down regulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99 (1997) 2334-2341
32. Ascher E., Scheinman M., Hingorani A., Seth P., Marella V.K., and Jacob T. Effect of p53 gene therapy combined with CTLA4Ig selective immunosuppression on prolonged neointima formation reduction in a rat model. Ann. Vasc. Surg. 14 (2000) 385-392
33. Tsui L.V., Camrud A., Mondesire J., Carlson P., Zayek N., Camrud L., et al. p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion. Circ. Res. 89 (2001) 323-328
34. Condorelli G., Aycock J.K., Frati G., and Napoli C. Mutated p21/WAF/CIP transgene overexpression reduces smooth muscle cell proliferation, macrophage deposition, oxidation-sensitive mechanisms, and restenosis in hypercholesterolemic apolipoprotein E knockout mice. FASEB J. 15 (2001) 2162-2170
35. Maillard L., Van Belle E., Smith R.C., Le Roux A., Denefle P., Steg G., et al. Percutaneous delivery of the gax gene inhibits vessel stenosis in a rabbit model of balloon angioplasty. Cardiovasc. Res. 35 (1997) 536-546
36. Maillard L., Van Belle E., Tio F.O., Rivard A., Kearney M., Branellec D., et al. Effect of percutaneous adenovirus-mediated Gax gene delivery to the arterial wall in double-injured atheromatous stented rabbit iliac arteries. Gene Ther. 7 (2000) 1353-1361
37. Wu C.H., Lin C.S., Hung J.S., Wu C.J., Lo P.H., Jin G., et al. Inhibition of neointimal formation in porcine coronary artery by a Ras mutant. J. Surg. Res. 99 (2001) 100-106
38. Indolfi C., Avvedimento E.V., Rapacciuolo A., Esposito G., Di Lorenzo E., Leccia A., et al. In vivo gene transfer: prevention of neointima formation by inhibition of mitogen-activated protein kinase kinase. Basic Res. Cardiol. 92 (1997) 378-384
39. Izumi Y., Kim S., Namba M., Yasumoto H., Miyazaki H., Hoshiga M., et al. Gene transfer of dominant-negative mutants of extracellular signal-regulated kinase and c-Jun NH2-terminal kinase prevents neointimal formation in balloon-injured rat artery. Circ. Res. 88 (2001) 1120-1126
40. Forough R., Koyama N., Hasenstab D., Lea H., Clowes M., Nikkari S.T., et al. Over expression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ. Res. 79 (1996) 812-820
41. Dollery C.M., Humphries S.E., McClelland A., Latchman D.S., and McEwan J.R. Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation 99 (1999) 3199-3205
42. Cheng L., Mantile G., Pauly R., Nater C., Felici A., Monticone R., et al. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation 98 (1998) 2195-2201
43. George S.J., Lloyd C.T., Angelini G.D., Newby A.C., and Baker A.H. Inhibition of late vain graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 101 (2000) 296-304
44. Barolet A.W., Nili N., Cheema A., Robinson R., Natarajan M.K., O'Blenes S., et al. Arterial elastase activity after balloon angioplasty and effects of elafin, an elastase inhibitor. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1269-1274
45. Hasenstab D., Lea H., and Clowes A.W. Local plasminogen activator inhibitor type 1 overexpression in rat carotid artery enhances thrombosis and endothelial regeneration while inhibiting intimal thickening. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 853-859
46. DeYoung M.B., Tom C., and Dichek D.A. Plasminogen activator inhibitor type 1 increases neointima formation in balloon-injured rat carotid arteries. Circulation 104 (2001) 1972-1981
47. Quax P.H., Lamfers M.L., Lardenoye J.H., Grimbergen J.M., de Vries M.R., Slomp J., et al. Adenoviral expression of a urokinase receptor-targeted protease inhibitor inhibits neointima formation in murine and human blood vessels. Circulation 103 (2001) 562-569
48. Kibbe M.R., Billiar T.R., and Tzeng E. Gene therapy for restenosis. Circ. Res. 86 (2000) 829-833
49. von der Leyen H.E., Gibbons G.H., Morishita R., Lewis N.P., Zhang L., Nakajima M., et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 1137-1141
50. Chen D., Krasinski K., Sylvester A., Chen J., Nisen P.D., and Andres V. Down regulation of cyclin-dependent kinase 2 activity and cyclin A promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery. J. Clin. Invest. 99 (1997) 2334-2341
51. Janssens S., Flaherty D., Nong Z., Varenne O., van Pelt N., Haustermans C., et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 97 (1998) 1274-1281
52. Varenne O., Sinnaeve P., Gillijns H., Iung B., Laurysens V., Meurrens K., et al. Percutaneous gene therapy using recombinant adenoviruses encoding human herpes simplex virus thymidine kinase, human PAI-1, and human NOS3 in balloon-injured porcine coronary arteries. Hum. Gene Ther. 11 (2000) 1329-1339
53. Billiar T.R. Nitric oxide. Novel biology with clinical relevance. Ann. Surg. 221 (1995) 339-349 [Review]
54. Shears II L.L., Kibbe M.R., Murdock A.D., Billiar T.R., Lizonova A., Kovesdi I., et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J. Am. Coll. Surg. 187 (1998) 295-306
55. Sinnaeve P., Chiche J.D., Nong Z., Varenne O., Van Pelt N., Gillijns H., et al. Soluble guanylate cyclase alpha(1) and beta(1) gene transfer increases NO responsiveness and reduces neointima formation after balloon injury in rats via antiproliferative and antimigratory effects. Circ. Res. 88 (2001) 103-109
56. Sinnaeve P., Chiche J.D., Gillijns H., Van Pelt N., Wirthlin D., Van De Werf F., et al. Over expression of a constitutively active protein kinase G mutant reduces neointima formation and in-stent restenosis. Circulation 105 (2002) 2911-2916
57. Mori E., Komori K., Yamaoka T., Tanii M., Kataoka C., Takeshita A., et al. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 105 (2002) 2905-2910
58. Van Belle E., Tio F.O., Chen D., Maillard L., Chen D., Kearney M., et al. Passivation of metallic stents after arterial gene transfer of phVEGF165 inhibits thrombus formation and intimal thickening. J. Am. Coll. Cardiol. 29 (1997) 1371-1379
59. Hiltunen M.O., Laitinen M., Turunen M.P., Jeltsch M., Hartikainen J., Rissanen T.T., et al. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation 102 (2000) 2262-2268
60. Morishige K., Shimokawa H., Yamawaki T., Miyata K., Eto Y., Kandabashi T., et al. Local adenovirus-mediated transfer of C-type natriuretic peptide suppresses vascular remodeling in porcine coronary arteries in vivo. J. Am. Coll. Cardiol. 35 (2000) 1040-1047
61. Todaka T., Yokoyama C., Yanamoto H., Hashimoto N., Nagata I., Tsukahara T., et al. Gene transfer of human prostacyclin synthase prevents neointimal formation after carotid balloon injury in rats. Stroke 30 (1999) 419-426
62. Zoldhelyi P., McNatt J., Xu X.M., Loose-Mitchell D., Meidell R.S., Clubb Jr. F.J., et al. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 93 (1996) 10-17
63. Lombardi J.V., Naji M., Larson R.A., Ryan S.V., Naji A., Koeberlein B., et al. Adenoviral mediated uteroglobin gene transfer to the adventitia reduces arterial intimal hyperplasia. J. Surg. Res. 99 (2001) 377-380
64. Eto Y., Shimokawa H., Hiroki J., Morishige K., Kandabashi T., Matsumoto Y., et al. Gene transfer of dominant negative Rho kinase suppresses neointimal formation after balloon injury in pigs. Am. J. Physiol.: Heart Circ. Physiol. 278 (2000) 1744-1750
65. Rajasingh J., Bord E., Luedemann C., Asai J., Hamada H., Thorne T., et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J. 20 (2006) 2112-2114
66. Haudenschild C.C., and Gould K.E. Vascular organ culture: prevention of endothelial damage due to removal and reperfusion. Scan. Electron Microsc. 3 (1979) 865-872
67. Teirstein P.S., and Kuntz R.E. New frontiers in interventional cardiology: intravascular radiation to prevent restenosis. Circulation 104 (2001) 2620-2626
68. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106 (2002) 2649-2651
69. Asahara T., Chen D., Tsurumi Y., Kearney M., Rossow S., Passeri J., et al. Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. Circulation 94 (1996) 3291-3302
70. Laitinen M., Pakkanen T., Donetti E., Baetta R., Luoma J., Lehtolainen P., et al. Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid-liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. Hum. Gene Ther. 8 (1997) 1645-1650
71. Walter D.H., Cejna M., Diaz-Sandoval L., Willis S., Kirkwood L., Stratford P.W., et al. Local gene transfer of phVEGF-2 plasmid by gene-eluting stents: an alternative strategy for inhibition of restenosis. Circulation 110 (2004) 36-45
72. Ohno N., Itoh H., Ikeda T., Ueyama K., Yamahara K., Doi K., et al. Accelerated reendothelialization with suppressed thrombogenic property and neointimal hyperplasia of rabbit jugular vein grafts by adenovirus-mediated gene transfer of C-type natriuretic peptide. Circulation 105 (2002) 1623-1626
73. Iwakura A., Luedemann C., Shastry S., Hanley A., Kearney M., Aikawa R., et al. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108 (2003) 3115-3121
74. Krasinski K., Spyridopoulos I., Kearney M., and Losordo D.W. In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty. Circulation 104 (2001) 1754-1766
75. Werner N., Nickenig G., and Laufs U. Pleiotropic effects of HMG-CoA reductase inhibitors. Basic Res. Cardiol. 97 (2002) 105-116 [Review]
76. Hanna A.K., Fox J.C., Neschis D.G., Safford S.D., Swain J.L., and Golden M.A. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J. Vasc. Surg. 25 (1997) 320-325
77. Deguchi J., Namba T., Hamada H., Nakaoka T., Abe J., Sato O., et al. Targeting endogenous platelet-derived growth factor B-chain by adenovirus-mediated gene transfer potently inhibits in vivo smooth muscle proliferation after arterial injury. Gene Ther. 6 (1999) 956-965
78. Kearney M., Pieczek A., Haley L., Losordo D.W., Andres V., Schainfeld R., et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation 95 (1997) 1998-2002
79. Waksman R., Raizner A.E., Yeung A.C., Lansky A.J., and Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet 359 (2002) 551-557 [Erratum in: Lancet 359 (2002) 1950.]
80. Waksman R., Bhargava B., Mintz G.S., Mehran R., Lansky A.J., Satler L.F., et al. Late total occlusion after intracoronary brachytherapy for patients with in-stent restenosis. J. Am. Coll. Cardiol. 36 (2000) 65-68
81. Waksman R., Ajani A.E., Pinnow E., Cheneau E., Leborgne L., Dieble R., et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 106 (2002) 776-778
82. Farb A., Heller P.F., Shroff S., Cheng L., Kolodgie F.D., Carter A.J., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
83. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
84. Davies M.J., Woolf N., Rowles P.M., and Pepper J. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br. Heart J. 60 (1988) 459-464
85. Schwarcz T.H., Yates G.N., Ghobrial M., and Baker W.H. Pathologic characteristics of recurrent carotid artery stenosis. J. Vasc. Surg. 5 (1987) 280-288
86. Gravanis M.B., and Roubin G.S. Histopathologic phenomena at the site of percutaneous transluminal coronary angioplasty: the problem of restenosis. Hum. Pathol. 20 (1989) 477-485
87. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., Li T., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
88. Shi Q., Rafii S., Wu M.H., Wijelath E.S., Yu C., Ishida A., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 92 (1998) 362-367
89. Werner N., Priller J., Laufs U., Endres M., Bohm M., Dirnagl U., et al. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1567-1572
90. Strehlow K., Werner N., Berweiler J., Link A., Dirnagl U., Priller J., et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 (2003) 3059-3065
91. Werner N., Junk S., Laufs U., Link A., Walenta K., Bohm M., et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ. Res. 93 (2003) 17-24
92. Makinen K., Manninen H., Hedman M., Matsi P., Mussalo H., Alhava E., et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther. 6 (2002) 127-133
93. Mann M.J., Whittemore A.D., Donaldson M.C., Belkin M., Conte M.S., Polak J.F., et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 354 (1999) 1493-1498
94. Kutryk M.J., Foley D.P., van den Br M., Hamburger J.N., van der Giessen W.J., deFeyter P.J., et al. Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis: results of the randomized investigation by the thorax center of antisense DNA using local delivery and IVUS after coronary stenting (ITALICS) trial. J. Am. Coll. Cardiol. 39 (2002) 281-287